A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients With Metastatic Refractory Soft Tissue Sarcoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Jun 2018
At a glance
- Drugs Cabozantinib (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 12 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 04 Apr 2018 Planned End Date changed from 31 Mar 2018 to 31 Mar 2019.
- 04 Apr 2018 Planned primary completion date changed from 31 Mar 2018 to 31 Mar 2019.